Bank of New York Mellon Corp Increases Stock Holdings in Cencora, Inc. $COR

Bank of New York Mellon Corp increased its stake in Cencora, Inc. (NYSE:COR) by 1.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,087,424 shares of the company’s stock after acquiring an additional 16,076 shares during the quarter. Bank of New York Mellon Corp’s holdings in Cencora were worth $339,853,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Acadian Asset Management LLC boosted its holdings in Cencora by 947.5% in the 2nd quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock worth $77,069,000 after buying an additional 232,539 shares during the last quarter. Segment Wealth Management LLC acquired a new stake in shares of Cencora in the third quarter worth approximately $4,830,000. Synergy Asset Management LLC purchased a new stake in shares of Cencora during the third quarter worth approximately $10,093,000. Exchange Traded Concepts LLC raised its stake in Cencora by 312.7% in the 3rd quarter. Exchange Traded Concepts LLC now owns 10,458 shares of the company’s stock valued at $3,268,000 after purchasing an additional 7,924 shares during the last quarter. Finally, Central Pacific Bank Trust Division lifted its holdings in Cencora by 654.6% in the 3rd quarter. Central Pacific Bank Trust Division now owns 4,188 shares of the company’s stock valued at $1,309,000 after purchasing an additional 3,633 shares in the last quarter. 97.52% of the stock is owned by hedge funds and other institutional investors.

Cencora Stock Up 0.3%

Shares of NYSE COR opened at $351.49 on Friday. The company has a market capitalization of $68.19 billion, a P/E ratio of 44.21, a P/E/G ratio of 1.67 and a beta of 0.66. The company has a debt-to-equity ratio of 4.32, a current ratio of 0.90 and a quick ratio of 0.55. The company has a 50 day simple moving average of $347.75 and a 200-day simple moving average of $323.44. Cencora, Inc. has a 1 year low of $237.71 and a 1 year high of $377.54.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The company had revenue of $83.73 billion during the quarter, compared to analyst estimates of $83.36 billion. During the same period in the prior year, the business posted $3.34 earnings per share. The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities research analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, November 14th. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. Cencora’s dividend payout ratio is currently 30.19%.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Cencora in a report on Monday, December 29th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a research note on Thursday, November 6th. Bank of America lowered their target price on Cencora from $380.00 to $360.00 and set a “neutral” rating on the stock in a report on Monday, January 5th. Wells Fargo & Company increased their price target on Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Finally, Robert W. Baird set a $415.00 price objective on Cencora in a research note on Tuesday, January 13th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $393.08.

Insiders Place Their Bets

In related news, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president owned 18,796 shares in the company, valued at approximately $6,484,620. This trade represents a 8.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Elizabeth S. Campbell sold 3,351 shares of the company’s stock in a transaction on Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. This trade represents a 12.30% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 20,316 shares of company stock valued at $7,151,265 over the last 90 days. 0.38% of the stock is owned by company insiders.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.